Reply: “Physical frailty is the most important predictor of early mortality in hospitalized patients with decompensated cirrhosis” Authors: Francesca D’Arcangelo, Alberto Zanetto Published: 2026 To the editor, We would like to thank Dr Li for her insightful comment on our prospective study regarding the role of physical frailty as a predictor of adverse outcome in hospitalized patients with decompensated cirrhosis.1 We would like to clarify that no patient had any neurological conditions such as cerebellar disorders, stroke, or brain tumors, which could have impacted the results of the performance tests. Dr Li raised concerns that the presence of hepatic encephalopathy (HE) may have influenced, at least in part, both frailty assessment and patient survival, thereby reducing the predictive value of frailty in this study, given that the prevalence of hepatic encephalopathy was higher among frail patients than among non-frail patients (35.5% vs. 23.1%). Unfortunately, it is not easy to determine the direction of causality between frailty and HE (ie, whether frail patients are more likely to develop HE or whether HE contributes to the development of frailty. It is also worth noting that, although the prevalence of HE was higher in the frail cohort, the difference was not statistically significant. This is consistent with the findings reported by Serper et al2 in whom the prevalence of concomitant HE was comparable between frail and non-frail patients (75% vs. 76%, respectively). Moreover, in the multicenter study by Segev et al,3 including outpatients with cirrhosis, those with frailty had a higher prevalence of HE at baseline than non-frail patients (57% vs. 36%, p<0.001). However, in multivariable adjusted models, only frailty remained independently associated with waitlist mortality. We fully share Dr Li’s perspective that frailty may be closely associated with the progression of acute-on-chronic liver failure (ACLF) and that frail patients may be more susceptible to developing ACLF during the course of their illness. We agree that further investigations, particularly dynamic, stage-based assessments of patients’ ACLF status over time, are needed to provide more robust evidence and to clarify whether frailty can be considered the strongest predictor of mortality. Nevertheless, even if frailty is not the strongest prognostic factor, it should be recognized as an important adverse predictor of outcomes, particularly in the setting of ACLF and acute decompensation requiring hospital admission. We hope that our study will stimulate further research exploring the role of frailty among hospitalized patients.